Stock Track | AKESO Soars 5.07% Intraday as Ivonescimab Data Selected for ASCO Plenary Presentation

Stock Track

May 29

AKESO's stock surged 5.07% during intraday trading on Friday, driven by positive market sentiment surrounding an upcoming key data presentation at a major medical conference.

The company's core product ivonescimab's HARMONi-6 study has been selected for a plenary session oral presentation at the ASCO Annual Meeting. This marks the first time a First-in-Class bispecific antibody from China has been featured in an ASCO plenary session, and it's the only China-originated innovative drug study in this year's plenary lineup.

The presentation will disclose overall survival data from a head-to-head comparison against tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer. This comes after the stock had been under sustained pressure following disappointing interim results from the global Phase III HARMONi-3 study, with today's rebound suggesting the imminent plenary data release is serving as a near-term re-rating catalyst.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1105051912"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105051912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105051912?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 11:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105051912","market":"nz","top_or_hot":-1,"title":"Stock Track | AKESO Soars 5.07% Intraday as Ivonescimab Data Selected for ASCO Plenary Presentation","media":"Stock Track","content":"<p>AKESO's stock surged 5.07% during intraday trading on Friday, driven by positive market sentiment surrounding an upcoming key data presentation at a major medical conference.</p><p>The company's core product ivonescimab's HARMONi-6 study has been selected for a plenary session oral presentation at the ASCO Annual Meeting. This marks the first time a First-in-Class bispecific antibody from China has been featured in an ASCO plenary session, and it's the only China-originated innovative drug study in this year's plenary lineup.</p><p>The presentation will disclose overall survival data from a head-to-head comparison against tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer. This comes after the stock had been under sustained pressure following disappointing interim results from the global Phase III HARMONi-3 study, with today's rebound suggesting the imminent plenary data release is serving as a near-term re-rating catalyst.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Soars 5.07% Intraday as Ivonescimab Data Selected for ASCO Plenary Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Soars 5.07% Intraday as Ivonescimab Data Selected for ASCO Plenary Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-29 11:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO's stock surged 5.07% during intraday trading on Friday, driven by positive market sentiment surrounding an upcoming key data presentation at a major medical conference.</p><p>The company's core product ivonescimab's HARMONi-6 study has been selected for a plenary session oral presentation at the ASCO Annual Meeting. This marks the first time a First-in-Class bispecific antibody from China has been featured in an ASCO plenary session, and it's the only China-originated innovative drug study in this year's plenary lineup.</p><p>The presentation will disclose overall survival data from a head-to-head comparison against tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer. This comes after the stock had been under sustained pressure following disappointing interim results from the global Phase III HARMONi-3 study, with today's rebound suggesting the imminent plenary data release is serving as a near-term re-rating catalyst.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1105051912","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105051912","pubTimestamp":1780025025,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock surged 5.07% during intraday trading on Friday, driven by positive market sentiment surrounding an upcoming key data presentation at a major medical conference.The company's core...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|康方生物盘中大涨5.07%Ivonescimab数据入选ASCO全会陈述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock surged 5.07% during intraday trading on Friday, driven by positive market sentiment surrounding an upcoming key data presentation at a major medical conference.The company's core product ivonescimab's HARMONi-6 study has been selected for a plenary session oral presentation at the ASCO Annual Meeting. This marks the first time a First-in-Class bispecific antibody from China has been featured in an ASCO plenary session, and it's the only China-originated innovative drug study in this year's plenary lineup.The presentation will disclose overall survival data from a head-to-head comparison against tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer. This comes after the stock had been under sustained pressure following disappointing interim results from the global Phase III HARMONi-3 study, with today's rebound suggesting the imminent plenary data release is serving as a near-term re-rating catalyst.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}